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Methods: We conducted a systematic review and meta-analysis to investigate the diagnostic utility
of RNFL thickness measurement using OCT in dementia (including Alzheimer’s disease [AD] and
mild cognitive impairment [MCI]) compared with healthy controls (HC).
Results: Seventeen studies comparing AD with HC (702 AD eyes and 790 HC eyes) were included,
demonstrating a significant reduction in mean RNFL thickness in AD (weighted mean difference
[WMD] 12.44, 95% confidence interval or CI [216.64, 28.25], P ,.0001). Five studies comparing
MCI and HC (214MCI eyes and 421 HC eyes) were included demonstrating a significant reduction in
mean RNFL thickness in MCI (WMD 28.23, 95% CI [214.00, 22.45], P 5.005). No relevant
studies were identified for other dementias.
Discussion: OCT measurement of RNFL thickness appears diagnostically useful in discriminating
between AD, or MCI, and HC.
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Pathological changes in the eye have recently been
reported in a range of neurodegenerative diseases. The retina
is essentially an extension of the brain, and shares embryo-
logical origins with regions responsible for cognition [1].
Visual symptoms, including impaired visual fields and acu-
ity are commonly reported in early Alzheimer’s disease
(AD) [2]. Optical coherence tomography (OCT) is a nonin-
vasive, noncontact optical scanning method, for cross-
sectional imaging of the internal retinal structure. As a
clinical imaging device, the operation is straightforwarduthor. Tel.: 144-(0)131-4659500; Fax: 144-(0)131-
mes.cameron@ed.ac.uk
16/j.dadm.2015.03.001
he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).and patient satisfaction is extremely high thanks to its fast
acquisition (just a few seconds) and noncontact scan. Ad-
vancements in the technology of the light source and
detector in recent years now permit extremely detailed visu-
alization and precise measurement of the retinal layers,
including the retinal nerve fiber layer (RNFL). The RNFL
consists of the unmyelinated axons of the retinal ganglion
cells, which together form the optic nerve and anterior visual
pathways [3]. Measurement of the RNFL thickness in the
retina is therefore a measurement of axonal loss in the ante-
rior visual pathways.
Thinning of the RNFL has been described in a range of
neurological disorders includingmultiple sclerosis [3], Parkin-
son’s disease [4], andneuromyelitis optica [4].Recently,RNFL
thinning in patients with AD [4–13] and mild cognitive
impairment (MCI) [11,12,14] have also been reported.imer’s Association. This is an open access article under the CC BY-NC-ND
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because of retrograde degeneration of the retinal ganglion
cell axons [9], and these changes have been suggested to
occur even before memory is affected [15]. There is also a
suggestion that neuroretinal atrophy may occur as a result
of amyloid-b plaque deposits within the retina, although
this hypothesis remains more speculative [7].
We aimed to conduct a systematic review andmeta-analysis
of the literature to determine the diagnostic utility ofOCTmea-
surement of the RNFL thickness in various dementias,
including AD, frontotemporal dementia (FTD), dementia
with Lewy bodies (DLB), vascular dementia (VaD), andMCI.2. Methods
2.1. Search strategy and study selection
We systematically searched the Medical Literature Anal-
ysis and Retrieval System Online (MEDLINE) and the Ex-
cerpta Medica Database (EMBASE) via OVID for all
human studies published until September 2014, in all lan-
guages. The Medical Subject Heading (MeSH) search terms
used were: (1) “dementia”, (2) “Alzheimer disease”, (3) “de-
mentia, vascular”, (4) “dementia, multi-infarct”, (5) “Lewy
body disease”, (6) “mild cognitive impairment”, and (7) “to-
mography”, (8) “tomography, optical coherence”, and (9)
“OCT”. We searched Web of Knowledge, Scopus, and Goo-
gle Scholar for all studies published before and including
September 2014 using the MeSH terms: (1) “optical coher-
ence tomography”, (2) “OCT”, and (3) “dementia”, (4) “Alz-
heimer”, (5) “mild cognitive impairment”, and (6) “MCI”.
Further studies were identified through reference and cita-
tion searching of relevant articles, and hand-searching of
relevant journals.
2.2. Inclusion and exclusion criteria
Inclusion criteria were: (1) original study; (2) study of
diagnostic utility of OCT; (3) diagnosis of dementia based
on appropriate criteria for the diagnosis of AD, such as the
National Institute of Neurological, Communicative Diseases
and Stroke and Alzheimer’s Disease and Related Disorders
Association [16]; (4) diagnosis of AD, FTD, DLB, VaD, or
MCI; (5) comparison of RNFL thickness in patients versus
control; (6) total subjects in the study of at least 10; and
(7) age and sex-matched control group.
We excluded the following studies: (1) review articles; (2)
abstract-only studies; (3) case reports; and (4) studies of
cerebral autosomal-dominant arteriopathy with subcortical
infarcts and leukoencephalopathy dementia.
2.3. Data extraction
We initially screened all studies identified in the system-
atic search of the online databases by abstract and title. Irrel-
evant or duplicate studies were removed, and the remaining
articles were assessed for eligibility by full-text review. Dataextracted from these studies included: title; authors; center;
publication year; aim of study; study type; disease focus;
number of patients and controls; characteristics of patients
including male:female ratio, mean age, and participant
selection criteria; diagnostic criteria; method of OCT used;
and results and authors’ suggestions.
2.4. Quality assessment
We assessed all full-text studies included in data analysis
using the Quality Assessment for Diagnostic Accuracy
Studies tool to determine the risk of bias and variability in
each study [17].
2.5. Statistical analysis
We extracted original data from the studies (means, stan-
dard deviations, sample sizes) and where required calculated
data which were not available. We used RevMan 5.3 (Co-
chrane Collaboration, Oxford, United Kingdom) [18] for the
meta-analysis of these continuous outcomes, calculating the
summary estimates including 95% confidence intervals
(CIs). We used the means, standard deviations, and sample
sizes extracted from the studies to calculate the weighted
mean difference (WMD) using the inverse-variance
random-effects model. A P value of less than .05 was consid-
ered to be statistically significant. To assess heterogeneity, we
used the chi-squared test, tau-squared, and the Higgins I2 test,
with an I2 value of more than 50% being significantly hetero-
geneous. We performed subgroup analysis according to the
type of OCT used and whether one or both eyes were used
per subject. We also performed sensitivity analysis to further
evaluate the heterogeneity by excluding studies where the
required data had to be calculated from the data provided.
We used funnel plot to assess for possible publication bias.3. Results
Five hundred and fifty-five studies were identified in the
literature search, with a further three identified through cita-
tion searching and hand-searching. Two hundred and thirty-
six were duplicates and therefore removed, leaving 322
studies which were screened by abstract and title only; 288
were deemed ineligible at this stage, and a further eight
studies were excluded as thesewere abstract only conference
presentations. Seven studies were removed; three were
deemed ineligible after full text review as they did not mea-
sure the RNFL, one study was a duplicate, another study did
not compare RNFL thickness in patients to controls, and two
studies reported insufficient data for analysis. Nineteen arti-
cles were therefore eligible; 17 compared AD to controls
(totalling 702 AD eyes and 790 control eyes) with 5 studies
comparing MCI to controls (totalling 214 MCI eyes and 421
control eyes); 3 of these 19 studies compared both AD and
MCI.
Thirteen studies determined the RNFL thickness in pa-
tients with AD compared with healthy controls (HC), seven
K.L. Thomson et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 136-143138of which used spectral domain OCT (SD-OCT) and six used
time domain (TD-OCT). Eleven articles reported the mean
overall RNFL thickness (Table 1 and Fig. 1), and 11 also re-
ported the RNFL thickness by quadrant (superior, inferior,
temporal, and nasal) (Table 2). Three articles also compared
the overall RNFL thickness in patients with MCI compared
with controls (Table 3 and Fig. 2), and two of these articles
reported RNFL thickness by quadrant (Table 4). No eligible
studies determined the RNFL thickness in patients with
FTD, DLB, or VaD.
3.1. RNFL thickness in AD patients compared with
controls
We identified a total of 17 studies including 702 AD eyes
and 790 control eyes. There was a significant reduction in
the overall mean RNFL thickness in AD patients compared
with controls (WMD 212.44, 95% CI [216.64, 28.25],
P,.0001) (Table 1, Fig. 1).We identified 14 studies including
588 AD eyes and 698 control eyes assessing the mean RNFL
thickness by quadrant, all of which demonstrated significant
reduction in patients with AD compared with HC; superior
quadrant (WMD 217.07, 95% CI [225.26, 28.89],
P ,.0001); inferior (WMD 216.62, 95% CI [224.48,
28.76], P ,.0001); temporal (WMD 28.71, 95% CI
[213.66, 23.76], P 5.0006); and nasal (WMD 29.35, 95%
CI [214.33,24.38], P5.0002) (Table 2, Appendix A).
Significant heterogeneity was identified between the
studies, with values of heterogeneity for overall mean
RNFL thickness of tau2 67.27, chi2 377.84, df 16Table 1
AD vs. normal controls: overall RNFL thickness
Study
OCT
type
One or
both eyes
Number of
subjects (eyes)
AD Controls
Ascaso et al. [9] TD Both 18 (36) 41 (82)
Berisha et al. [14] TD One 9 (9) 8 (8)
Chi et al.[19] TD One 12 (12) 17 (17)
Garcia-Martin et al. [15] SD One 20 (20) 28 (28)
Gharbiya et al. [20] SD Both 21 (42) 21 (42)
G€unes et al. [5] SD One 40 (40) 40 (40)
Iseri et al. [12] TD Both 14 (28) 15 (30)
Kang et al. [8] SD Both 8 (16) 8 (16)
Kesler et al. [10] TD Mix 30 (52) 24 (38)
Kirbas et al. [7] SD Both 40 (80) 40 (80)
Kromer et al. [21] SD Mix 22 (42) 22 (42)
Larrosa et al. [22] SD One 151 (151) 61 (61)
Moreno-Ramos et al. [23] SD Both 10 (20) 10 (20)
Paquet et al. [11] TD Both 26 (52) 15 (30)
Parisi et al. [13] TD One 17 (17) 14 (14)
Polo et al. [6] SD One 75 (75) 75 (75)
Zhu et al. [24] SD NR 10 (NR) 167 (NR)
Abbreviations: AD, Alzheimer’s disease; RNFL, retinal nerve fiber layer; OCT
SD, spectral domain; NR, not reported.
NOTE. One or both eyes or a mix of one and both eyes used per subject in the e
brackets).
*P , 0.05, **P , 0.01, ***P , 0.001.(P ,.00001), and I2 96%. Therefore we further evaluated
the studies by performing subgroup analysis and sensitivity
analysis (Appendix C). We performed two subgroup ana-
lyses: (1) type of OCT used (TD-OCT or SD-OCT), (2)
one or both eyes used per subject (excluding studies where
a mix of one and both eyes were used). In the subgroup anal-
ysis according to the type of OCT used, there were 7
TD-OCT studies and 10 SD-OCT studies for the overall
mean RNFL thickness, and 6 TD-OCT and 8 SD-OCT
studies for the RNFL thickness by quadrant. There were sta-
tistically significant reductions in the overall, inferior and
temporal RNFL thickness regardless of whether TD-OCT
or SD-OCTwas used. The TD-OCT studies showed a larger
weighted mean difference for the overall mean RNFL thick-
ness compared with the SD-OCT studies (TD-OCT WMD
220.89, 95% CI [229.32, 212.45], P ,.00001; SD-OCT
WMD 26.92, 95% CI [211.66, 22.18], P 5.004). We
also further analyzed the TD-OCT and SD-OCT studies
based on the OCT model used. Heterogeneity became
nonsignificant within the Spectralis and Cirrus model anal-
ysis, but was still present within the other models.
In the subgroup analysis according to one or both eyes used
per subject, therewere seven studies each for the overall mean
RNFL thickness, and seven “one eye” studies and five “both
eyes” studies for the RNFL thickness by quadrant. There
were statistically significant reductions in the overall, superior
and inferiorRNFL thickness regardless ofwhether oneor both
eyes were used. In the sensitivity analysis, we excluded the
studies where the required data had to be calculated fromMean age
6 SD (yrs)
Overall mean RNFL
thickness 6 SD (mm)
AD Controls AD Controls
AD and MCI:
72.1 6 8.7
72.9 6 7.9 64.96 6 16.71*** 103.1 6 8.04
74.3 6 3.3 74.3 6 5.8 85.5 6 7.4 93.8 6 10.4
75.39 6 7.30 75.29 6 5.84 93.18 6 11.36 99.44 6 8.88
79.3 6 4.1 72.1 6 5.1 88.6 6 20.5 89.2 6 20.9
73.1 6 6.9 70.3 6 7.3 96.8 6 6.9 95.9 6 8.5
75.02 6 6.34 74.15 6 5.76 84.0 6 7.0*** 107.1 6 6.3
70.16 6 9.7 65.1 6 9.8 87.46 6 23.78*** 113.16 6 6.72
71.5 67.4 80.44 6 16.73* 92.50 6 9.8
73.7 6 9.9 70.9 6 9.2 84.7 6 10.6* 94.3 6 11.3
69.3 6 4.9 68.9 6 5.1 65.0 6 6.2*** 75.0 6 3.8
75.9 6 6.1 64.0 6 8.2 105 6 17.0 101.8 6 10.7
75.29 74.87 97.55 6 14.12 100.55 6 12.99
73.0 6 6.5 70.2 6 5.5 94.5 6 2.2*** 108.0 6 2.2
78.5 6 4.91 75.5 6 5.1 83.4 6 7.19** 102.2 6 1.8
70.37 6 6.1 Age-matched 59.5 6 16.7** 99.9 6 8.95
74.15 6 9.15 73.98 6 9.05 97.40 6 11.2 99.21 6 9.9
79.6 6 8.6 75.5 6 7.7 90.7 6 15.8*** 96.7 6 9.6
, optical coherence tomography; SD, standard deviation; TD, time-domain;
valuation of mean RNFL thickness. Number of subjects (number of eyes in
Study or Subgroup
Ascaso 2014
Berisha 2007
Chi 2010
Garcia-Martin 2014
Gharbiya 2014
Gunes 2014
Iseri 2006
Kang 2013
Kesler 2011
Kirbas 2013
Kromer 2014
Larrosa 2014
Moreno-Ramos 2013
Paquet 2007
Parisi 2001
Polo 2014
Zhu 2014
Total (95% CI)
Heterogeneity: Tau² = 67.27; Chi² = 377.84, df = 16 (P < 0.00001); I² = 96%
Test for overall effect: Z = 5.82 (P < 0.00001)
Mean
64.96
85.5
93.18
88.6
96.8
84
87.46
80.44
84.7
65
105
97.55
94.5
83.4
59.5
97.4
90.7
SD
16.71
7.4
11.36
20.5
6.9
7
23.78
16.73
10.6
6.2
17
14.12
2.2
7.19
16.7
11.2
15.8
Total
36
9
12
20
42
40
28
16
52
80
42
151
20
52
17
75
10
702
Mean
103.1
93.8
99.44
89.2
95.9
107.1
113.16
92.5
94.3
75
101.8
100.55
108
102.2
99.9
99.21
96.7
SD
8.04
10.4
8.88
20.9
8.5
6.3
6.72
9.8
11.3
3.8
10.7
12.99
2.2
1.8
8.95
9.9
9.6
Total
82
8
17
28
42
40
30
16
38
80
42
61
20
30
14
75
167
790
Weight
6.0%
5.3%
5.5%
4.4%
6.5%
6.6%
5.1%
5.0%
6.3%
6.7%
6.0%
6.4%
6.8%
6.7%
5.1%
6.5%
4.9%
100.0%
IV, Random, 95% CI
-38.14 [-43.87, -32.41]
-8.30 [-16.98, 0.38]
-6.26 [-13.95, 1.43]
-0.60 [-12.46, 11.26]
0.90 [-2.41, 4.21]
-23.10 [-26.02, -20.18]
-25.70 [-34.83, -16.57]
-12.06 [-21.56, -2.56]
-9.60 [-14.21, -4.99]
-10.00 [-11.59, -8.41]
3.20 [-2.87, 9.27]
-3.00 [-6.96, 0.96]
-13.50 [-14.86, -12.14]
-18.80 [-20.86, -16.74]
-40.40 [-49.62, -31.18]
-1.81 [-5.19, 1.57]
-6.00 [-15.90, 3.90]
-12.44 [-16.64, -8.25]
AD Controls Mean Difference Mean Difference
IV, Random, 95% CI
-100 -50 0 50 100
AD Controls
Fig. 1. Meta-analysis of Alzheimer’s disease (AD) vs. normal controls: overall retinal nerve fiber layer (RNFL) thickness.
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Martin et al. [15], Paquet et al. [11], Polo et al. [6]). Statisti-
cally significant reductions in the overall, superior, inferior,
temporal, and nasal RNFL thickness remained.Heterogeneity
was reduced but still present within the subgroup and sensi-
tivity analyses, therefore the random-effect model was used
allowing for heterogeneity. Funnel plots did not show any cor-
relation between the study size and effect size.
3.2. RNFL thickness in MCI patients compared with
controls
We identified five studies including 214MCI eyes and 421
control eyes, demonstrating a significant reduction in the
overall mean RNFL thickness in patients with MCI (WMD
28.23, 95% CI [214.00, 22.45], P 5.005) (Table 3,
Fig. 2). There were four studies including 168 MCI eyes
and 391 control eyes for the mean RNFL thickness by quad-
rant, showing significant reduction in all four quadrants; su-
perior (WMD 211.72, 95% CI [222.59, 20.85], P 5.03);
inferior (WMD 211.45, 95% CI [221.00, 21.90],
P 5.02); temporal (WMD 26.47, 95% CI [210.74,
22.20], P 5.003); and nasal (WMD 24.34, 95% CI
[28.50, 20.19], P 5.04) (Table 4, Appendix B). There was
significant heterogeneity between the studies, with values
of heterogeneity for overall mean RNFL thickness of tau2
40.61, chi2 91.67, df 4 (P ,.00001), and I2 96%. Therefore,
we performed subgroup analysis according to the type of
OCT used (Appendix C). There were three TD-OCT studiesand two SD-OCT studies for the overall mean RNFL thick-
ness and two studies each for the RNFL thickness by quad-
rant. Only the TD-OCT studies showed a significant
reduction in the overall, inferior, temporal, and nasal RNFL
thickness, whereas the SD-OCT studies only showed a signif-
icant reduction in the superior RNFL thickness. Heterogene-
ity became nonsignificant within the TD-OCT studies for the
inferior, temporal, and nasal quadrants, and within the SD-
OCT studies for the overall, superior, inferior, and nasal quad-
rants. A sensitivity analysis excluding Ascaso et al. [9]
(where the required data had to be calculated) only showed
a significant reduction in the superior and temporal RNFL
thickness, with no significant reduction in the overall, infe-
rior, and nasal RNFL thickness.4. Discussion
The measurement of RNFL thickness using OCT appears
to be a promising method to aid in the diagnosis of various
neurodegenerative diseases, including AD. Many studies
have reported a significant decrease in the mean overall
RNFL thickness in patients with AD [5–13], and some have
reported significant reductions in the individual quadrants.
The superior [5,6,9,12–14,26] and inferior quadrants [5,6,8–
10,12,13,26] demonstrating the greatest thinning in patients
with AD compared with HC in most studies, whereas the
nasal [5,8,9,12,13,26] and temporal [5,9,13,26] quadrants
are only found to be significantly thinner in few studies.
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MCI [9–11]. Ascaso et al. [9] determined overall RNFL
thickness and RNFL thickness in all quadrants to be signif-
icantly thinner in patients with amnestic type MCI compared
with controls, and conversely to be significantly thicker in
patients with MCI compared with patients with AD. Howev-
er, Kesler et al. [10] report a significant difference between
patients with MCI and patients with AD only in the overall
RNFL thickness and in the inferior quadrant.
The correlation between clinical severity of AD and over-
all RNFL thickness is not well established. Although some
studies report a significant association between Mini-
Mental State Examination scores (MMSE) and RNFL thick-
ness [9], most articles analyzed in this systematic review
found no significant difference [5,7,10,13,14]. Iseri et al.
[12] reported a strong correlation between the macular vol-
ume and MMSE scores, but not RNFL thickness.
Detection of RNFL thinning may also be of prognostic
benefit; one prospective case control study reported the abil-
ity of OCT measurement of RNFL thickness to predict the
risk of cognitive decline in healthy patients [27]. Further
studies are, however, required before firm conclusions about
OCTs role in prognostication can be made.
Two different generations of OCT technology have been
used in the articles analyzed in this systematic review: time-
domain OCT (TD-OCT) and spectral-domain OCT (SD-
OCT) (also known as Fourier domain). SD-OCT is the
more recent technology, and shows considerable improve-
ments over TD-OCT in every aspect of image acquisition,
processing, and analysis [3]. The image resolution is
improved from 10 to 4 mm, and the speed of acquisition is
dramatically improved from around 400 A-scans/second to
40,000/second. Studies using these two generations of tech-
nology cannot therefore be directly compared; however, in
the articles analyzed within this systematic review, RNFL
thinning in patients with AD can be detected on any OCT
machine, whether TD-OCT or SD-OCT.
All the studies analyzed had age-matched controls with
no significant difference in age between the patients with
AD, MCI, and HC, with the exception of Iseri et al. [12].
Age-matching is highly important for the analysis of
RNFL thickness, as the RNFL is known to become thinner
with natural ageing in HC [27]. Each study excluded patients
with any other eye pathology, such as glaucoma and diabetic
retinopathy, to prevent ophthalmological comorbidities from
having a confounding effect.
The studies analyzed in this systematic review suggest
that the significant thinning of the RNFL does occur in
AD, and that OCT can be successfully used to detect these
changes. A previous meta-analysis [28] of seven different
articles studying the RNFL thickness in AD compared
with controls, all of which used TD-OCT, determined
that there is a significant reduction in RNFL thickness in
AD patients compared with HC, overall and in all four in-
dividual quadrants. However, the previous meta-analysis
grouped patients with AD and MCI together for analysis,
Table 3
MCI vs normal controls: overall RNFL thickness
Study OCT type
One or
both eyes
Number of subjects
(eyes) Mean age 6 SD (yrs)
Overall mean RNFL
thickness 6 SD (mm)
MCI Controls MCI Controls MCI Controls
Ascaso et al. [9] TD Both 18 (36) 41 (82) AD and MCI:
72.1 6 8.7
72.9 6 7.9 86.7 6 7.18*** 103.1 6 8.04
Kesler et al. [10] TD Mix 24 (40) 24 (38) 71.0 6 10.0 70.9 6 9.2 85.8 6 10.0* 94.3 6 11.3
Paquet et al. [11] TD Both 23 (46) 15 (30) 78.7 6 6.2 75.5 6 5.1 89.3 6 2.7*** 102.2 6 1.8
Shen et al. [25] SD Mix 23 (45) 52 (104) 74.4 6 3.2 74.1 6 2.6 82.6 6 10.5 85.6 6 10.2
Zhu et al. [24] SD NR 47 (NR) 167 (NR) 76.1 6 8.2 75.5 6 7.7 96.8 6 9.9*** 96.7 6 9.6
Abbreviations: MCI, mild cognitive impairment; RNFL, retinal nerve fiber layer; OCT, optical coherence tomography; SD, standard deviation; TD, time-
domain; SD, spectral domain; NR, not reported.
NOTE. One or both eyes or a mix of one and both eyes used per subject in the evaluation of mean RNFL thickness. Number of subjects (number of eyes in
brackets).
*P , 0.05, **P , 0.01, ***P , 0.001.
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nificant difference in RNFL thickness between patients
with MCI and those with AD [9]. This study has the advan-
tage of analyzing patients with MCI and patients with AD
separately, and also provides an updated review of the liter-
ature, which is required after the explosion of studies in
this area in recent years. This article includes six new arti-
cles and a total of 381 eyes of patients with AD and 84
eyes of patients with MCI compared with 187 patient
eyes in the previous systematic review. Additionally, the
technology of OCT has advanced and our meta-analysis in-
cludes studies using the higher resolution SD-OCT, lacking
from the previous review [28].
There are, however, a number of important limitations
which must be considered. No studies included the histo-
pathological confirmation of diagnosis; clinical diagnostic
criteria in recent use for AD often fail to robustly differen-
tiate accurately between AD and non-AD pathology with
up to 40% of patients diagnosed with non-AD dementias
identified as having pathology consistent with AD at post-
mortem in some series [29]. Furthermore, all studies
included were cross-sectional; no conclusions can therefore
be drawn regarding the timing of RNFL thinning, or of
change over time (including any changes detectable at theStudy or Subgroup
Ascaso 2014
Kesler 2011
Paquet 2007
Shen 2014
Zhu 2014
Total (95% CI)
Heterogeneity: Tau² = 40.61; Chi² = 91.67, df = 4 (P < 0.00001); I² = 96%
Test for overall effect: Z = 2.79 (P = 0.005)
Mean
86.7
85.8
89.3
82.6
96.8
SD
7.18
10
2.7
10.5
9.9
Total
36
40
46
45
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214
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103.1
94.3
102.2
85.6
96.7
SD
8.04
11.3
1.8
10.2
9.6
Total
82
38
30
104
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421
Weight
20.3%
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100.0%
I
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-
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Fig. 2. Meta-analysis of mild cognitive impairment (MCI) vs. normpreclinical stages of dementia). The screening of controls
for cognitive symptoms was also not reported by any study,
nor did any undertake bedside cognitive testing, biomarker
or functional imaging studies (such as amyloid PET) on con-
trols. It may therefore be speculated that the control group
may have included those with preclinical dementia, thereby
lowering the estimates of differences between groups. Esti-
mates of differences are also potentially limited by the small
and underpowered size of most of the studies included.
Finally, one of the aims of this study was to establish the
clinical utility of OCT in differentiating between dementia
subtypes (such as AD and FTD), unfortunately no studies
examining the use of OCT in any other forms of dementia
beyond AD met the inclusion criteria. This important ques-
tion therefore remains unanswered for other common syn-
dromes such as FTD, DLB, and VaD. There is also no
consensus yet in the current literature as to the cut-off value
or the type of RNFL thickness (overall or individual quad-
rants) which would best distinguish between AD/MCI and
controls, thus precluding the use of sensitivity and specificity
which requires a binary classification. Therefore, although
this study showed a significant reduction in RNFL thickness
in AD compared with controls, this does not directly trans-
late to a measurement of diagnostic utility (sensitivity andV, Random, 95% CI
.40 [-19.32, -13.48]
8.50 [-13.24, -3.76]
.90 [-13.91, -11.89]
-3.00 [-6.64, 0.64]
0.10 [-3.08, 3.28]
8.23 [-14.00, -2.45]
ean Difference Mean Difference
IV, Random, 95% CI
-100 -50 0 50 100
MCI Controls
al controls: overall retinal nerve fiber layer (RNFL) thickness.
Table 4
MCI vs. normal controls: RNFL thickness by quadrant
Study
Superior Inferior Temporal Nasal
MCI Controls MCI Controls MCI Controls MCI Controls
Ascaso et al. [9] 100.3 6 15.5*** 127.4 6 14.0 110.6 6 18.1*** 134.2 6 15.57 67.38 6 14.32*** 75.34 6 15.05 68.43 6 17.16*** 76.84 6 15.0
Kesler et al. [10] 101.3 6 15.2 110.0 6 16.7 111.9 6 16.1* 127.0 6 15.5 64.2 6 13.9 67.8 6 15.1 65.9 6 15.1 76.4 6 21.8
Shen et al. [25] 101.8 6 16.8 104.7 6 15.4 104.5 6 17.6 109.3 6 21.3 62.7 6 12.2 65.5 6 10.1 61.5 6 8.1 64.8 6 8.4
Zhu et al. [24] 117.1 6 18.3** 125.2 6 20.6 128.7 6 17.2 131.4 6 20.1 73.1 6 13.5*** 84.3 6 13.8 67.6 6 12.2 67.1 6 14.0
Abbreviations: MCI, mild cognitive impairment; RNFL, retinal nerve fiber layer.
NOTE. *P , .05, **P , .01, ***P , .001 for RNFL thickness in MCI compared with controls as reported by the studies.
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after consensus on the appropriate criteria.
With the rapid pace of advances in OCT technology, we
will soon see even greater resolution and detail in the retina.
In addition, software improvements are already enabling
automated segmentation and measurement of other inner
retinal layers, such as the ganglion cell body layer. This
may provide additional insights into the pathology of these
neurodegenerative conditions. However, the true value and
significance of OCT measures of neuroretinal integrity
may lie in its integration with other retinal metrics (such
as retinal vessel morphology), as part of multimodal retinal
imaging. The retinal vasculature is a well-established proxy
of both systemic and cerebral microvascular health [30,31]
with changes in retinal vascular calibre previously reported
in association with cognitive decline. Wider retinal venules
are associated with an increased risk of vascular dementia
[32], whereas narrower and less tortuous venules have
been measured in patients with AD [33,34]. The potential
exists therefore for detailed and integrated retinal image
analysis to provide meaningful information about our
brain in health and disease.5. Conclusions
The measurement of mean overall RNFL thickness using
OCT appears to have the most potential diagnostic utility in
the diagnosis ofAD.Measurement of the thickness of individ-
ual RNFL quadrants may also be of benefit, although results
varied. OCT also appears to have diagnostic utility in MCI.
Further investigations are required to fully understand the
pathological processes behind RNFL thinning in AD and
MCI and the extent to which RNFL thinning is associated
with disease severity. Correlation with more sensitive and
specific cognitive tests, such as Addenbrooke’s Cognitive
Examination-III, formal neuropsychological evaluation,
and other biomarkers of dementia including imaging and
cerebrospinal fluid, has the potential to improve diagnostic
accuracy in the absence of histopathology.
Future, larger studies with predetermined power calcula-
tions and longitudinal data are required to investigate the
change in RNFL thickness over time to determine the use
of OCT as a potential surrogate marker in the prognostica-
tion of those with MCI. The inclusion of patients withother forms of dementia is also vital to allow the understand-
ing of RNFL disease specificity. Both of these areas are
necessary before concluding the true clinical utility of
OCT in dementia.Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.dadm.2015.03.001.RESEARCH IN CONTEXT
1. Systematic review: We searched Medical Literature
Analysis and Retrieval System Online, Excerpta
Medica Database, Web of Knowledge, Scopus, and
Google Scholar for all human studies published in
any language to September 2014. We systematically
evaluated studies included using the Excerpta
Medica Database Quality Assessment for Diagnostic
Accuracy Studies checklist and performed meta-
analysis of pooled results.
2. Interpretation: This is the most comprehensive sys-
tematic review and meta-analysis of retinal nerve
fiber layer (RNFL) thickness measurement using
optical coherence tomography in dementia to date.
Significant differences in pooled results were iden-
tified comparing both patients with Alzheimer’s
disease and mild cognitive impairment with healthy
controls, suggesting diagnostic utility.
3. Future directions: There is a need for further well-
powered prospective longitudinal studies of RNFL
measurement in different dementias, ideally with
post-mortem histopathology as a diagnostic gold
standard. Future work should also focus on the
diagnostic and prognostic value of combined mea-
surements of RNFL thickness and retinal vascula-
ture, potentially using a multimodal approach with
other clinical measures and biomarkers.
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